A novel estimand to adjust for rescue treatment in clinical trials by Michiels, Hege et al.
A novel estimand to adjust for rescue treatment
in clinical trials
Hege Michiels1, Cristina Sotto2, An Vandebosch2 and Stijn
Vansteelandt1,3
1Department of Applied Mathematics, Computer Science and Statistics,
Ghent University, Ghent, Belgium
2Janssen R&D, a division of Janssen Pharmaceutica NV, Beerse, Belgium
3Department of Medical Statistics, London School of Hygiene and
Tropical Medicine, London, UK
Abstract
The interpretation of randomised clinical trial results is often complicated by intercurrent
events. For instance, rescue medication is sometimes given to patients in response to
worsening of their disease, either in addition to the randomised treatment or in its place.
The use of such medication complicates the interpretation of the intention-to-treat anal-
ysis. In view of this, we propose a novel estimand defined as the intention-to-treat effect
that would have been observed, had patients on the active arm been switched to rescue
medication if and only if they would have been switched when randomised to control.
This enables us to disentangle the treatment effect from the effect of rescue medication
on a patient’s outcome, while avoiding the strong extrapolations that are typically needed
when inferring what the intention-to-treat effect would have been in the absence of rescue
medication. We develop an inverse probability weighting method to estimate this esti-
mand under specific untestable assumptions, in view of which we propose a sensitivity
analysis. We use the method for the analysis of a clinical trial conducted by Janssen
Pharmaceuticals, in which chronically ill patients can switch to rescue medication for eth-
ical reasons. Monte Carlo simulations confirm that the proposed estimator is unbiased in
moderate sample sizes.
Keywords : Intercurrent events, Treatment switching, Causal inference, Post-treatment
confounding, Mediation, Treatment discontinuation
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1 Introduction
The ICH E9(R1) addendum (International Council for Harmonisation, 2019 [6]) proposes
a structured framework for clinical trial design, conduct, analysis and interpretation. It
aligns the main objective of the clinical trial with the treatment effect to be estimated,
called ‘estimand’. An estimand defines the target of estimation for a particular trial
objective. The description of an estimand thus reflects the clinical question of interest,
considering intercurrent events such as discontinuation of assigned treatment, use of an
additional or alternative treatment and terminal events such as death. In this paper, we
focus on the intercurrent event where patients start (additional) non-randomised med-
ication because of an exacerbation of symptoms or insufficient therapeutic effect. For
example, in a trial of dietary intervention to reduce high blood pressure, a patient may be
rescued by starting antihypertensive medication when his blood pressure fails to respond
(White et al., 2001 [34]). Likewise, patients in oncology trials may sometimes start a new
anticancer regimen before observing the endpoint of interest upon disease progression
(Degtyarev et al., 2019 [3]).
The use of rescue medication complicates the interpretation of trial results, especially
when its use is imbalanced between treatment arms, in which case it typically reduces
the observed treatment effect in an ‘intention-to-treat’ or ‘treatment policy’ analysis.
Ignoring all data after switching to rescue medication is likely to deliver biased results
since rescued patients or ‘switchers’ form a highly selective group. One estimand described
in the ICH E9(R1) addendum which aims to accommodate this uses the ‘hypothetical
strategy’, where a scenario is envisaged in which the intercurrent event would not occur,
e.g. in which the additional medication was not available. While this removes the effect
of switching, thereby delivering insight into the pure effect of the randomised treatments,
this scenario may not be realistic when the additional medication must be available for
ethical reasons. In addition, strong extrapolations may be needed to infer what the
intention-to-treat effect would have been in the absence of rescue medication. To lessen
the extent of extrapolation, we propose a novel estimand, called ‘balanced estimand’, and
define it as the intention-to-treat effect that would have been observed, had patients on the
active arm been switched to rescue medication if and only if they had been switched when
randomised to control. As such, we are able to distinguish the effect of the experimental
treatment from the effect of rescue medication on a patient’s outcome, by defining a
treatment effect that would be observed if rescue treatment were balanced across both
arms. The proposed estimand is a variant of the hypothetical estimand discussed in the
ICH E9(R1) addendum and corresponds to a so-called ‘natural direct effect’ (Robins and
Greenland, 1992 [16]) that can be expressed in terms of potential outcomes (Rubin, 1974
[19]).
Existing methods for natural direct effects are not readily applicable, however, because
the association between rescue treatment and outcome is typically confounded by vari-
ables, such as disease severity, which are themselves affected by the treatment. Such
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post-treatment confounding poses major challenges (Daniel et al., 2015 [1]). We accom-
modate this via a novel sensitivity analysis method. In particular, we propose a novel
inverse probability weighting approach for estimating this effect in settings where the
decision to switch to rescue medication is made at one pre-specified time point.
We use the proposed method for the analysis of a clinical trial conducted by Janssen
Pharmaceuticals, in which chronically ill patients can switch to rescue medication for
ethical reasons. In addition, we perform Monte Carlo simulations to investigate the finite
sample performance of the estimator.
2 Setting
Suppose the data consist of independent and identically distributed observations {(Yi, Si,
Li, Ri,Ci) : i = 1, . . . , n}, where C represents measured baseline covariates, Y the out-
come and R the randomised treatment which is coded 1 for patients assigned to active
treatment and 0 for those assigned to control. Variable Y can represent a binary or
continuous outcome, but we assume that it is not a censored time-to-event (survival)
outcome. In addition, S is a binary variable indicating whether the patient switched to
rescue treatment during the study (S = 1) or not (S = 0). This rescue medication can
either be taken in addition to the randomised treatment or in its place. In this paper,
we consider the simple setting where patients can only switch at one pre-specified time
point in the trial. We assume that whether or not the patient switches during the study
is determined by clinicians based on the information contained in the baseline covariates
C (e.g. age) along with the possibly high-dimensional post-treatment covariates L (e.g.
disease severity). Within the ‘counterfactual’ or ‘potential outcomes’ framework (Rubin,
1974 [19]; Robins, 1986 [15]; Pearl, 1995 [11]), we let Y r denote the potential outcome
that would have been observed under treatment R = r (r ∈ {0, 1}) and Y rs the potential
outcome that would have been observed under treatment R = r and switching status
S = s (s ∈ {0, 1}). Similarly, Lr represents the severity of disease under treatment R = r
and Sr the switching status if R = r.
Throughout this paper, we consider a long-term prevention trial in patients who are
asymptomatic at risk for developing Alzheimer’s dementia, as described by Polverejan
and Dragalin (2019 [13]). In this simulation case study, an experimental treatment is
compared to placebo in slowing cognitive decline, measured by the ADCS-PACC score
(Donohue et al., 2014 [4]). The primary endpoint is the change in ADCS-PACC score
from baseline to month 54. One of the intercurrent events considered by the authors is
the initiation of treatment with cholinesterase inhibitors during the course of the trial.
This rescue medication is given if medically indicated and may deliver therapeutic benefit
due to the symptomatic effects of cholinesterase inhibitors. In this example, we assume
for illustrative purposes that the change in ADCS-PACC score from baseline to month 26
is an indicator for the severity of disease, and is used to determine whether the patient
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should initiate treatment with cholinesterase inhibitors.
2.1 Handling intercurrent events
Descriptions of three different strategies to handle intercurrent events are listed below,
each reflecting a different clinical question of interest in the above setting (Interna-
tional Council for Harmonisation, 2019 [6]). First, in the ‘treatment policy strategy’
or ‘intention-to-treat effect’ E (Y 1 − Y 0), the occurrence of the intercurrent event is con-
sidered irrelevant in defining the treatment effect of interest. By ignoring whether or
not the patient took rescue medication, the treatment effect targeted by this estimand is
a combined effect of the initial randomised treatment and the treatment modified as a
result of the rescue medication. Typically, rescue treatment leads to a reduced outcome
difference between treatment regimens, which may make it seem easier to demonstrate
non-inferiority or equivalence between arms (Ratitch et al., 2020 [14]). In such cases,
it may be difficult to make decisions about the efficacy of treatment regimens. This is
illustrated by a toy example with binary outcome in table 1. It shows the potential out-
comes under treatment and control of five patients who have access to rescue medication
during the trial. Some of these patients would never switch to rescue treatment, regard-
less of the assigned treatment, some would always switch and some would switch only if
assigned to control. Although the experimental treatment has a beneficial inherent effect
on the outcome of patients, this is not captured here by the treatment policy estimand.
In particular, we illustrate that this beneficial effect can be diluted if more patients would
switch to rescue medication under control than under treatment since rescue medication
positively influences the outcome.
Next, we take a closer look at the ‘hypothetical strategy’, where the intercurrent event is
seen as a mediating factor for inference about the treatment regimen of interest. The goal
is to estimate the treatment effect under a hypothetical scenario, where the intercurrent
event is removed, for example, what would have happen-ed if rescue medication was not
available. Using the potential outcomes framework this can be expressed as E (Y 10 − Y 00),
with Y r0 the outcome of a patient that would have been observed if (s)he was assigned to
treatment r ∈ {0, 1} and did not switch to rescue treatment during the trial (S = 0). This
estimand is again illustrated in table 1. This hypothetical strategy clearly distinguishes
the effect of the randomised treatment from the effect of rescue treatment, but is prone to
extrapolation when it is difficult to consider not giving rescue medication to some patients,
as is the case in the Alzheimer’s disease example. In addition, the scenario ‘if patients
had no access to rescue medication’ is sometimes criticized because it is incompatible with
ethical conduct since patients cannot be forced to adhere (Mallinckrodt et al., 2017 [8];
Permutt, 2016 [12]), thereby also raising questions about the relevance of this effect for
policy making.
Finally, we consider the ‘principal stratification strategy’, where the objective is to es-
timate the treatment effect for the patients who would never need to switch to rescue
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therapy, regardless of the assigned treatment: E (Y 1 − Y 0|S0 = S1 = 0). Since for each
patient we only observe what happens on the treatment to which (s)he was randomised, it
is not possible to observe which principal stratum the patient belongs to. Consequently,
the principal stratification estimand represents the treatment effect for an unknown and
non-identifiable group of patients. In addition, the subgroup of patients that would never
need rescue therapy, referred to as the ‘always-compliers’ or ‘always-takers’ (e.g. Vander-
Weele, 2011 [27]), is typically a selective subgroup of the population, making it difficult to
generalise conclusions to the broader level of the patient population. In our toy example
in table 1, the principal stratum of patients who would never switch is a small subgroup
of the considered population. Estimation of the principal stratification effect relies, like
the other discussed estimands, on unverifiable assumptions. However, the assumptions
necessary to identify the principal stratification effect are generally stronger since they
relate to the joint distribution of the counterfactuals S0 and S1.
Estimand Potential outcomes Treatment effect estimate
Treatment
policy
Y 1 E(Y 1 − Y 0)
= 3/5− 3/5
= 0Y
0
Hypothetical Y 10 E(Y 10 − Y 00)
= 3/5− 2/5
= 1/5Y
00
Principal
stratification
Y 1 E(Y 1 − Y 0|S0 = S1 = 0)
= 2/2− 1/2
= 1/2Y
0
Balanced Y 1S
0
E(Y 1S
0 − Y 0)
= 4/5− 3/5
= 1/5Y
0
Table 1: Toy example with five patients to illustrate the estimands discussed using the
potential outcomes. The outcome Y is binary. Meaning of the smileys:
: Y = 1 (success) and patient did not switch to rescue
: Y = 0 (failure) and patient did not switch to rescue
: Y = 1 (success) and patient did switch to rescue
: Y = 0 (failure) and patient did switch to rescue
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2.2 Balanced estimand
To lessen the extent of extrapolation, we here propose a novel estimand, defined as the
treatment effect that would have been observed in the setting where the use of rescue
treatment were balanced across both arms. In particular, we consider the intention-to-
treat effect that would have been observed, had patients on the active arm been switched
to rescue medication if and only if they would have been switched when randomised to
control. By doing this, we disentangle the effect of rescue medication from the effect of
the randomised treatment. This is tantamount to disentangling the treatment pathways
R→ Y and R→ L→ Y from the switching pathways R→ S → Y and R→ L→ S → Y
in the causal diagram in figure 1.
R Y
L
C
S
Figure 1: Causal diagram with treatment R, outcome Y , severity of disease L, switching
status S and baseline covariates C.
Within the potential outcomes framework, we let Y rS
0
denote the potential outcome
that would have been observed for a patient if (s)he was assigned to treatment r ∈ {0, 1},
but would switch as under control. For a patient who would need to switch to rescue
treatment if s(he) was assigned to control, S0 equals 1 and consequently, Y 1S
0
= Y 11
represents the outcome that would have been observed if this patient was assigned to
treatment, but switched to rescue medication during the trial. Similarly, for a patient
who would not switch to rescue treatment if s(he) was assigned to control, S0 equals 0
and Y 1S
0
= Y 10 represents the outcome that would have been observed if this patient
was assigned to treatment and stayed on treatment during the entire trial. Finally, Y 0S
0
is the outcome of a patient if (s)he was in the control group and would switch as under
control. Therefore, Y 0S
0
can also be written as Y 0 , the outcome that would have been
observed if the patient was assigned to the control arm of the trial. Using this notation,
the proposed treatment effect can be expressed as the natural direct effect (Robins and
Greenland, 1992 [16])
µ := E
(
Y 1S
0 − Y 0S0
)
= E
(
Y 1S
0 − Y 0
)
. (1)
The toy example in table 1 illustrates that this balanced estimand defines an effect for
the entire study population, with the use of rescue treatment being balanced across both
arms. In the context of the Alzheimer’s dementia study, E(Y 1S
0
) is the average change in
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cognitive score if all patients would be assigned to experimental treatment but would ini-
tiate rescue medication only if they would do this under placebo. By doing so, we envisage
a realistic hypothetical scenario where patients have access to rescue medication, but its
mediating effect is removed by keeping the patients who switch fixed across both arms.
It can be defined according to the guidelines of the ICH E9(R1) addendum (International
Council for Harmonisation, 2019 [6]), as shown in appendix A.1.
The proposed balanced estimand (1) corresponds to the natural direct effect where
switching is fixed to the natural value it would have been under control. However, in some
situations (see later), it may be more interesting or relevant to fix the switching status
to the natural value it would have been under experimental treatment: E
(
Y 1 − Y 0S1
)
.
This natural direct effect can be estimated using the methods described for estimating
(1) below, upon interchanging the meaning of R = 0 and R = 1.
3 Identification
For simplicity, we assume randomisation to be independent of baseline covariates, i.e.
R ⊥ C. However, if randomisation depends on certain baseline covariates, as is the case
under stratified randomisation, the proposed method can easily be adjusted by replacing
the marginal probability P (R) by the conditional probability P (R|C) in the identification
results below (see appendix A.2). Identification of µ relies on consistency and randomised
assignment which implies R ⊥ Y r and R ⊥ (Y 1s, S0,L1,C) for r, s ∈ {0, 1}. The second
part of effect (1), µ0 := E(Y
0), can then simply be identified as the average outcome in
the control arm:
µ0 = E(Y
0) = E(Y 0|R = 0) = E(Y |R = 0).
The first part of effect (1), µ1 := E
(
Y 1S
0
)
, cannot be identified from the observed data
without making untestable assumptions since the counterfactual outcomes Y 1S
0
are not
observable. In particular, we will assume that the potential decision to switch Sr can be
fully attributed to the baseline covariates and severity of disease in the sense that it has
no residual dependence on the potential outcomes Y 1s i.e., Sr ⊥ Y 1s|L,C (s, r ∈ {0, 1})
(see appendix A.2 for further details). Under these assumptions, µ1 can be rewritten as
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a weighted average outcome among the patients in the treatment group:
µ1 = E
(
Y 1S
0
)
=
∫
E(Y 1s|L1 = l,C)P (S0 = s|L1 = l,C)f(L1 = l|C)f(C)dsdldC
=
∫
E(Y |S = s,L = l, R = 1,C)P (S = s|L1 = l, R = 0,C)f(L = l|R = 1,C)f(C)dsdldC
= E
[
Y
R
P (R = 1)
W (S,L1,C)
]
, (2)
with weights
W (S,L1,C) :=
P (S|L1, R = 0,C)
P (S|L1, R = 1,C) .
Identity (2) shows that the above assumptions are not sufficient to identify µ1 because
P (S|L1, R = 0,C) is not identified. This can also be understood upon rewriting E
(
Y 1S
0
)
as E
(
Y 1L
1S0L
0
)
, which shows that identification requires information on the joint distri-
bution of L0 and L1, given C (Daniel et al., 2015 [1]). It is precisely this which has hin-
dered the development of natural direct effect estimates in the presence of post-treatment
confounders L (VanderWeele et al., 2014 [29]). Existing solutions have either added the
pathway R→ L→ S → Y to the direct treatment effect R→ Y , considered a hypothet-
ical scenario where the decision to switch is made independently of L (Vansteelandt and
Daniel, 2017 [32]) or considered a setting where L0 is independent of L1, given C (Robins
and Richardson, 2010 [17]). All of these are undesirable in our setting. In particular,
we argue that a large part of the treatment effect will arise by R having an effect on L.
Therefore, we aim to distinguish the direct pathways R → Y and R → L → Y from the
others. In view of this, we develop here a novel approach.
Given that L is potentially high-dimensional, we will herein avoid modelling the joint
distribution of L0 and L1. We will instead make assumptions that are sufficient to identify
the probability to switch a control patient, conditional on L1, i.e. P (S = 1|L1, R = 0,C).
In particular, since the decision to switch a control patient is based on his/her observed
health status L0, which will often be strongly correlated with L1, we will introduce a
‘dilution factor’ ρ which expresses to what extent the association between switching S and
severity of disease under treatment L1 is weaker in the control group than in the treatment
group. Specifically, assuming that P (S = 1|L1, R = 1,C) = expit(ω1 + ω ′2C + ω ′3L1), we
will model P (S = 1|L1, R = 0,C) as
P (S = 1|L1, R = 0,C) = expit(λ1 + λ′2C + ρω ′3L1), (3)
for given ρ, with unknown parameter values λ1 and λ
′
2. In appendix A.4, we show a data
generating mechanism under which this model is correctly specified. In appendix A.2, we
propose a more general model and discuss nonparametric identification.
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The sum λ1 − ω1 + (λ2 −ω2)′C + (ρ− 1)ω ′3L1 can be interpreted as the log odds ratio
for switching in the control group versus the treatment group:
exp{λ1 − ω1 + (λ2 −ω2)′C + (ρ− 1)ω ′3L1} =
odds(S = 1|R = 0,L1,C)
odds(S = 1|R = 1,L1,C) .
Here, (ρ− 1)ω ′3L1 represents the extent to which the association between switching and
severity of disease under treatments differs between the two treatment groups:
exp{(ρ− 1)ω ′3L1} =
odds(S = 1|R = 0,L1,C)/odds(S = 1|R = 1,L1,C)
odds(S = 1|R = 0,L1 = 0,C)/odds(S = 1|R = 1,L1 = 0,C) . (4)
Here, L1 = 0 is a reference value, e.g. not severely ill under treatment. The parameter ρ
needs to be specified by the user and can be used as a sensitivity parameter by repeating
the estimation of µ1 for a range of values ρ. Since ρ equals the correlation between L
0
and L1 conditional on C under certain data generating mechanisms (see appendix A.4),
varying ρ over the interval [0.8, 1] will often constitute a good choice. In particular, ρ = 1
implies
odds(S = 1|R = 0,L1,C)
odds(S = 1|R = 1,L1,C) =
odds(S = 1|R = 0,L1 = 0,C)
odds(S = 1|R = 1,L1 = 0,C) ,
in which case differences between the switching statuses in both treatment groups can be
fully attributed to the baseline covariates. This is generally implausible, suggesting that
ρ = 1 can be viewed as an upper bound.
4 Inverse probability weighting (IPW) estimator
From (2), it follows that µ1 can be estimated by calculating a weighted average of the
outcome of the treated patients using weights P (S|L
1,R=0,C)
P (S|L1,R=1,C) . This motivates the following
approach:
1. Fit a parametric model for the probability of switching in the treatment group:
P (S = 1|L, R = 1,C) = expit(ω1 +ω ′2C +ω ′3L).
2. Estimate parameter λ = (λ1,λ2)
′ in model P (S = 1|L1, R = 0,C) = expit(λ1 +
λ′2C + ρω
′
3L
1) by solving the following estimating equations:
0 =
n∑
i=1
(
1
Ci
)(
(1−Ri)(1− Si)
1− pˆi
− 1
pˆi
Ri(1− Si)
expit(ωˆ1 + ωˆ
′
2Ci + ωˆ
′
3Li)
{
exp
(
λ1 − ωˆ1 + (λ2 − ωˆ2)′Ci + (ρ− 1)ωˆ ′3Li
)− 1}+ 1
)
,
with pˆi = n−1
∑n
i=1Ri the sample mean of R and ωˆ1, ωˆ2 and ωˆ3 the estimators for
ω1, ω2 and ω3 obtained in step 1.
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3. Estimate the weights W (S,L,C):
W (1,L,C; λˆ, ωˆ) =
expit(λˆ1 + λˆ
′
2C + ρωˆ
′
3L)
expit(ωˆ1 + ωˆ
′
2C + ωˆ
′
3L)
for switchers, and
W (0,L,C; λˆ, ωˆ) =
1− expit(λˆ1 + λˆ
′
2C + ρωˆ
′
3L)
1− expit(ωˆ1 + ωˆ ′2C + ωˆ ′3L)
for non-switchers, with λˆ1 and λˆ2 the estimates for λ1 and λ2 obtained in step 2.
4. Estimate µ1 as the weighted average outcome
µˆ1 =
∑n
i=1 YiRiWi∑n
i=1RiWi
,
with Wi = W (Si,Li,Ci; λˆ, ωˆ).
5. Estimate µ0 as the weighted average outcome
µˆ0 =
∑n
i=1 Yi(1−Ri)∑n
i=1 1−Ri
.
Finally, µ is estimated as µˆ = µˆ1− µˆ0. The equations used in step 2 to estimate parameter
λ extract information from the marginal probability of switching under control treatment,
i.e. P (S = 1|R = 0,C) (see appendix A.2). As shown in appendix A.2, using these
equations to estimate λ leads to a consistent estimator for µ. The variance of µˆ can be
estimated using the nonparametric bootstrap or 1 over n times the sample variance of the
influence function (see appendix A.3). R code for this estimator is given in appendix B.
Even though randomisation is done independently of the baseline covariates C, im-
provement in the precision of the inverse probability weighted means can be made by
using propensity scores P (R = 1|C) estimated under more flexible models (Rotnitzky et
al., 2010 [18]), as explained in appendix A.2.
5 Simulations
We performed a simulation study to investigate the finite-sample performance of our
estimators. The settings considered are based on the long-term prevention trial in patients
who are asymptomatic at risk for developing Alzheimer’s dementia.
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5.1 Data generation
First, we generate the randomised treatment R ∼ Ber(0.5) and baseline covariate C ∼
N(0, 1). Both treatment groups are assumed to experience a decline in ADCS-PACC
scores, with negative mean changes from baseline. The change in score at month 26 is
used as variable L, indicating how seriously ill the patient is and mainly determining
whether the patient needs rescue medication. The potential change in the ADCS-PACC
score from baseline at month 26 under treatment is drawn as L1|C ∼ N(δ1 + δ2C, σ2L),
for all patients across both arms. The distribution of these values is illustrated in figure
3 in appendix C.1. The switching decision for patients in the treatment arm is generated
as S|L1, R = 1, C ∼ Bin(expit(ω1 + ω2C + ω3L1)), and for patients in the control arm as
S|L1, R = 0, C ∼ Bin(expit(λ1 + λ2C + ρω3L1)). The parameter values used to simulate
data are shown in table 4 in appendix C.1. Figure 2 in appendix C.1 illustrates the
assumed mean changes in cognitive score during the trial. The mean changes in scores L
of patients who do not switch to rescue medication follow a linear decline, with a slower
decrease for the treated patients compared to placebo patients. Switchers have lower L
values on average, but their decline in cognitive score slows down after starting rescue
medication. Finally, the observed change in the ADCS-PACC score from baseline at
month 54 is drawn as Y |S, L1, R, C ∼ N(α1 + α2S + α3L1 + α4C + α5(1−R), σ2Y ).
Three different settings were considered in the simulations. These settings differ in the
percentage of patients who switch, the effect of rescue medication on the cognitive score
and the strength of the effect of the score at month 26 on the decision to switch. Two
different sample sizes of 200 and 1000 are considered in the simulations. The performance
of our estimators was evaluated through a simulation analysis with 5000 runs for each
setting and sample size. The standard error of the estimators is calculated as the standard
deviation of the estimates.
5.2 Results
Table 2 summarizes the results of performed simulations for the IPW estimator, with
correctly specified sensitivity parameter ρ = 0.9. In addition, figure 4 in appendix C.2
shows boxplots with the simulation results. All estimators are approximately unbiased.
The estimator for µ1 has the lowest variance in scenario 1, when only 17% of patients
across both arms switch to rescue medication, compared to 39% in scenario 2 and 56% in
scenario 3. In addition, the dependence between L1 and switching is relatively weaker in
the first scenario, as seen in figure 2 in appendix C.1. The variance of µ in the first scenario
is similar to the variance of the treatment policy estimand, while the variance of µ in the
other two scenarios is about 4 times the variance of the treatment policy estimand (see
table 5 in appendix C.2). The skewness in the estimates for µ1 (see figure 4 in appendix
C.2) is caused by weight variability. In particular, large estimates for µ1 are caused by a
few data simulations where the weight W (S,L,C) of one treated patient, who switches
11
Scenario Sample Parameter Bias SE Weights
size
Scenario 1 200 µ -0.003 0.101
Large treatment effect
Limited switching effect
Switchers:
11% in R = 1
24% in R = 0
µ1 -0.003 0.080 0.437; 1.642
µ0 0.001 0.064
1000 µ 0 0.044
µ1 0 0.034 0.508; 1.895
µ0 0 0.028
Scenario 2 200 µ -0.021 0.122
Small treatment effect
Limited switching effect
Switchers:
24% in R = 1
54% in R = 0
µ1 -0.020 0.106 0.054; 2.132
µ0 0.001 0.059
1000 µ -0.004 0.058
µ1 -0.003 0.051 0.088; 2.24
µ0 0 0.026
Scenario 3 200 µ -0.062 0.164
Large treatment effect
Large switching effect
Switchers:
36% in R = 1
76% in R = 0
µ1 -0.062 0.156 0.010; 2.398
µ0 0.001 0.065
1000 µ -0.012 0.106
µ1 -0.011 0.102 0.023; 2.424
µ0 0 0.029
Table 2: lations investigating the finite sample size performance of the IPW estimator
proposed in section 4. The column ‘weights’ shows the 5% and 95% percentiles of the
weights Wi/n
−1∑n
j=1RjWj among the patients in the experimental treatment arm.
to rescue medication, becomes so large that it dominates the estimation. Truncation of
the weights W (S,L,C) at the 1% and 99% percentiles decreases the variability of the
estimates for µ1 (see table 6 in appendix C.2). However, this truncation causes the bias
to increase.
In table 5 in appendix C.2, we show simulation results for three different values of ρ. In
particular, we show the results for the IPW estimator if ρ is correctly specified (ρ = 0.9)
and if ρ is misspecified (ρ = 0.8 or 1). Since the differences in the obtained results in
terms of bias and SE are very limited, we find the proposed estimand not to be sensitive
to the specified value of this sensitivity parameter.
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6 Data analysis
In this section, we use the balanced estimand in the analysis of a clinical trial, in which
the efficacy and safety of an experimental treatment to improve glycaemic control was
tested for patients with type 2 diabetes mellitus (Stenlf et al., 2013 [24]) (ClinicalTri-
als.gov identifier: NCT01081834). In this 26-week, randomised, stratified, double-blind,
placebo-controlled, phase 3 trial, conducted by Janssen Pharmaceuticals, patients (n =
584) received canagliflozin 100 or 300 mg or placebo (1:1:1) once daily. Canagliflozin is a
sodium glucose co-transporter 2 inhibitor for type 2 diabetes mellitus. Randomisation was
stratified according to whether subjects were taking antihyperglycaemic agents (AHA) at
screening and whether they participated in the frequently-sampled mixed-meal tolerance
test (FS-MMTT). The primary endpoint of this study was the change from baseline in
haemoglobin A1c (HbA1c) at week 26, comparing both doses of the study medication sep-
arately to placebo. Study visits for this primary endpoint and other secondary endpoints,
were planned at baseline, week 6, week 12, week 18 and week 26. Baseline characteristics
are shown in table 7 in appendix D.2.
During this trial, glycaemic rescue therapy with metformin could be initiated if needed.
The decision to take this rescue medication was made by clinicians throughout the study
and was mainly based on the observed fasting plasma glucose (FPG) measurements. A
higher percentage of patients treated with placebo (22.7%) received glycaemic rescue
therapy compared to patients treated with canagliflozin 100 and 300 mg (2.6 and 2.0%).
In the primary analysis, the last observation carried forward (LOCF) approach was used to
impute the missing efficacy data. In particular, for patients who received rescue therapy,
the last post-baseline value prior to initiation of rescue therapy was used.
Here, we will estimate the treatment effect that would have been observed, had patients
on the placebo arm been switched to rescue medication if and only if they would have been
switched when randomised to canagliflozin 100 mg, i.e. E
(
Y 1 − Y 0S1
)
. The switching
status is fixed to the value it would have been under treatment and not the value it would
have been under placebo, since the large imbalance between the amount of switchers
in both groups can cause problems in the identification of P (S = 1|L1, R = 0,C) (see
appendix A.2 for further details). In this setting, the hypothetical estimand may also
be relevant since the percentage of switchers is very limited in the canagliflozin 100 mg
arm. In particular, we expect small differences between the balanced estimand and the
hypothetical estimand.
6.1 Methods
Efficacy analyses comparing canagliflozin 100 mg to placebo are performed by estimat-
ing the balanced estimand, the treatment policy or ITT estimand and the hypothetical
estimand using IPW estimators (see appendices D.3 and D.4). These estimands can be
defined according to the guidelines of the ICH E9(R1) guideline (see appendix D.1). The
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analysis set consists of all randomised patients who received at least one dose of the study
drug. Multiple imputations (MI) using chained equations (Van Buuren et al., 1999 [26])
were used to impute the missing efficacy data. We have complete data for 263 patients,
meaning that 124 patients had at least one missing observation (see table 8 in appendix
D.2). All baseline covariates except plasma glucose were fully observed. The observed
missing data pattern is close to monotone-missingness, but there are also occasional miss-
ing values due to patients missing just one study visit. Since all variables with missing
values are continuous, we used predictive mean matching as imputation method. All
observed baseline variables and 5 longitudinal variables (see tables 7 and 8 in appendix
D.2), together with the treatment arm, whether or not the patient switches to rescue
medication and the study visit at which the patient switches, were used as predictors
for the imputation models. These imputations models rely on the MAR assumption. In
total, 50 datasets were imputed using 10 iterations.
Even though patients could initiate rescue medication throughout the study, for this
illustration, we assume switching happened at one pre-specified time point. In addition,
we summarize the longitudinal FPG and HbA1c values by taking the average before
initiation of rescue medication for the switchers and the average before week 26 for the
non-switchers and use this as variable L (see figures 5, 6 and 7 in appendix D.2). The
baseline variables C that were used are shown in table 7 in appendix D.2. First, the
full logistic regression model for P (S = 1|L0, R = 0,C), including all variables as main
predictors, was fitted in every imputed dataset and pooled using Rubin’s rules (Rubin,
2004 [20]). Next, variable selection was performed using backward elimination, where
at each step the variable with the highest p-value was omitted, the new logistic model
was fitted in every dataset and pooled using Rubin’s rules. This was terminated when
all included predictors had a p-value below 10%. Afterwards, all two-by-two interactions
between the variables in the model were each in turn added to the model and kept if the
corresponding p-value was below 10%. For every imputed dataset, this results in a model
P (S = 1|L0, R = 0,C) = expit(ω1 + ω ′2C + q(L0,C)), with C the vector with selected
baseline covariates and interactions between them and q(L0,C) a linear combination of
the selected longitudinal covariates, interactions between them and interactions between
baseline covariates and longitudinal covariates. Next, µ is estimated in every imputed
dataset. The model for switching in the treatment group was determined as P (S =
1|L0, R = 1,C) = expit(λ1+λ′2C+ρq(L0,C)), where parameter λ = (λ1,λ2)′ is estimated
by solving estimating equations (equations (8) in appendix A.2). The standard errors
are obtained from 1000 nonparametric stratified bootstrap replications of each of the 50
imputed datasets and combined using Rubin’s rules. The 95% confidence intervals are
estimated as percentile intervals from the pooled sample of 50×1000 estimates for µ, µ1
and µ0. This method is described in Schomaker and Heumann (2018 [23]) as the ‘MI Boot
pooled sample method’. In addition, we estimated the standard errors of the balanced
estimand using the influence function (IF) (see appendix A.3).
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6.2 Results
Estimand Parameter Estimate (95% CI)
Balanced
(ρ = 1)
E(Y 1 − Y 0S1) -0.872 [-1.673, -0.494]
E(Y 1) -0.870 [ -0.992, -0.747]
E(Y 0S
1
) 0.003 [-0.354, 0.795]
Balanced
(ρ = 0.9)
E(Y 1 − Y 0S1) -0.874 [-1.678, -0.498]
E(Y 1) -0.870 [-0.992, -0.748]
E(Y 0S
1
) 0.004 [ -0.349, 0.801]
Balanced
(ρ = 0.8)
E(Y 1 − Y 0S1) -0.876 [-1.679, -0.496]
E(Y 1) -0.870 [-0.992, -0.748]
E(Y 0S
1
) 0.006 [-0.353, 0.796]
Treatment policy E(Y 1 − Y 0) -0.642 [-0.832, -0.453]
E(Y 1) -0.870 [-0.992, -0.748]
E(Y 0) -0.228 [-0.374, -0.084]
Hypothetical E(Y 10 − Y 00) -0.897 [-1.529, -0.552]
E(Y 10) -0.875 [-1.003, -0.746]
E(Y 00) 0.022 [-0.294, 0.649]
Table 3: Results of the data analysis comparing canagliflozin 100 mg to placebo.
Estimates for three different estimands regarding the intercurrent event ‘switching to
rescue medication’ are shown.
Table 3 summarizes the results of the data analysis, while the obtained models and
weights are shown in appendix D.5. The estimated balanced estimand for ρ = 0.9 (-
0.874 (bootstrap SE 0.295, IF SE 0.293)), indicates that the decrease from baseline in
HbA1c at week 26 would be 0.87% larger if all patients received canagliflozin 100 mg,
compared to placebo, while initiating rescue medication only if they would do that under
canagliflozin 100 mg. As expected, the treatment policy estimand leads to an attenuated
treatment effect (-0.642 (SE 0.097)) compared to the hypothetical estimand (-0.897 (SE
0.251)) and balanced estimand, since a much higher percentage of patients treated with
placebo received rescue therapy compared to patients treated with canagliflozin 100 mg.
In addition, the differences between the balanced estimand, where the switching status
is fixed to the value it would have been under active treatment, and the hypothetical
estimand are limited, since only 2.6% of the treated patients initiate rescue medication.
Finally, we find the novel estimand not to be sensitive to the specified value of ρ.
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7 Discussion
In this article, we have proposed a novel estimand for the treatment effect in clinical trials
where patients can take rescue medication in response to worsening of their disease. We
defined it as a natural direct effect and developed a novel inverse probability weighting
estimator for it, to account for post-treatment confounding. It is primarily relevant in
settings where treatment switches are not uncommon in both arms of the trial. Our pro-
posal relies on untestable assumptions, in view of which we proposed a sensitivity analysis.
Sensitivity analyses for settings with post-treatment confounding have been described pre-
viously in the literature. Imai and Yamamoto (2013 [5]) proposed a sensitivity analysis to
assess the robustness to potential violation of the assumption of no treatment-mediator
interactions, using linear structural equation models with random effects to model the
outcome and the mediator of interest. However, this approach is not readily applicable to
the context of rescue treatment in view of the linearity assumptions on the mediator, and
cannot easily accommodate multiple confounders. Vansteelandt and VanderWeele (2012
[30]) proposed a sensitivity analysis method for post-treatment confounding that involves
specifying a selection bias function. This function can be difficult to interpret, but evalu-
ates to zero in a large class of realistic data-generating mechanisms. Their technique, in
contrast to ours, requires a model for the density of the possibly high-dimensional con-
founders L. Concurrent work (Tchetgen Tchetgen and Shpitser, 2012 [25]; VanderWeele
and Chiba, 2014 [28]) does not assume that data is available on the post-treatment con-
founder L, but requires specification of a rather large number of sensitivity parameters.
It is less relevant to our setting where there is a good understanding of what the key
confounders are.
We used the proposed method for the analysis of a clinical trial conducted by Janssen
Pharmaceuticals, in which chronically ill patients can switch to rescue medication for
ethical reasons. Application to this clinical trial demonstrated adequate performance.
Monte Carlo simulations confirmed that the proposed estimator is unbiased in moderate
sample sizes. However, in some settings our approach can suffer from weight variability
as the weights can become so large that individual observations dominate the estimation.
This instability of IPW estimators in the presence of influential weights is a general
concern (Vansteelandt et al., 2010 [31]). In view of this, we plan to develop a more efficient
doubly robust estimator that relies on working models for the outcome and confounders,
as well as a model for the probability to be in the active treatment arm, but only requires
one of these to be correctly specified. In addition, use of such an estimator will be less
sensitive to bias from weight truncation.
In this paper, we considered the simple setting where patients can switch to rescue
medication at one time point during the trial. In future work, we hope to extend our
estimand to the setting where the decision to switch can be taken at different times for
different patients. This complicates the estimation of the treatment effect because it re-
quires methods for causal mediation analysis with longitudinal mediators and confounders
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where problems of post-treatment confounding are even more severe (Daniel et al., 2013
[2]). Likewise, challenges are foreseen to expand the proposed method to a censored time-
to-event (survival) outcome, in which case one must acknowledge that the event may
happen before rescue treatment is initiated.
The proposed estimator for the balanced estimand requires the collection of the outcome
after the intercurrent event. However, this is in line with the addendum of the ICH E9
guideline that states that all efforts should be made to collect all data that are relevant
to support estimation, including data that inform the characterisation, occurrence and
timing of intercurrent events.
The novel estimand is not only useful in the considered setting, but can also be used
to handle other intercurrent events such as treatment discontinuation. In that setting,
the balanced estimand targets the treatment effect that would have been observed, had
patients discontinued treatment if and only if they would have discontinued when ran-
domised to experimental treatment. In addition, the novel IPW estimator can more
generally be used to estimate natural direct effects where the association between the
mediator and the outcome is confounded by variables which are themselves affected by
the exposure.
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Appendices
A Proposed estimand
A.1 Estimands framework
The balanced estimand, proposed in section 2.2, can be defined according to the estimands
framework described in the addendum of the ICH E9(R1) guideline (International Council
for Harmonisation, 2019 [6]). In the context of the Alzheimer’s dementia study, this
estimand can be defined using the following attributes:
• Treatment: experimental treatment or placebo, as defined by the study protocol.
• Population: the entire study population, as defined by the inclusion-exclusion
criteria of the study.
• Variable: change from baseline to month 54 in the cognitive endpoint.
• Intercurrent events: switching to rescue medication: the hypothetical scenario is
envisaged where patients on the active arm had been switched to rescue medication
if and only if they would have been switched when randomised to placebo.
• Population-level summary: difference in means of the variable.
A.2 Identification
In this section, we show how µ1 can be identified in a much more general way than
proposed in section 3.
First, we allow the randomisation to depend on certain baseline covariates, e.g. we do
not assume R ⊥ C here. This ensures, for example, that the proposed method can be ap-
plied to a study with stratified randomisation. Consequently, the proposed approach only
relies on the following assumptions. The first assumption is the ignorability assumption
Y 1s ⊥ S|L, R = 1,C (s ∈ {0, 1}). To identify µ1, one also needs to rely on a so-called
cross-world independence assumption, i.e. Y 1s ⊥ S0|L1,C. According to Mittinty and
Vansteelandt (2019 [9]) this can be viewed as a strengthening of the other assumptions
needed to identify µ1. The ignorability assumption expresses that patients who would be
switchers versus non-switchers if given active treatment are exchangeable (within strata
of L1 and C) in terms of what their outcome would be if given active treatment and if
the switching status were set to s ∈ {0, 1}. The cross-worlds independence assumption
requires that patients who would be switchers versus non-switchers under control are ex-
changeable in terms of what their outcome would be under active treatment and if the
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switching status were set to s ∈ {0, 1}. In addition, identification of µ1 relies on ran-
domised assignment conditional on the baseline covariates C, which implies R ⊥ Y r|C
and R ⊥ (Y 1s, S0,L1,C) for r, s ∈ {0, 1}.
Second, we assumed the probability P (S = 1|L1, R = 1,C) to follow the parametric
model P (S = 1|L1, R = 1,C) = expit(ω1 +ω ′2C +ω ′3L1). In this appendix, we assume a
more general parametric model l(L1,C;ω) with unknown parameter value ω0.
Next, instead of assumption (3), we assume
P (S = 1|L1, R = 0,C)
= P (S = 1|L1, R = 1,C) exp {q0(C) + q1(L
1,C)}
E [exp {S(q0(C) + q1(L1,C))} |L1, R = 1,C] , (5)
with q0(C) an unknown function and q1(L
1,C) a known function that satisfies q1(0,C) = 0
for all C. Assumption (3) corresponds to the choices q0(C) = λ1 − ω1 + (λ2 − ω2)′C
and q1(L
1,C) = (ρ− 1)ω ′3L1 with ω ′3 the coefficient of L1 in the model l(L1,C;ω) =
expit(ω1+ω
′
2C+ω
′
3L
1). For patients with given severity of disease under treatment L1 and
baseline covariates C, the probability of switching S in the control group is thus assumed
to equal the probability of switching S in the treatment group tilted by an exponential
function. Tilt functions have previously been proposed for handling nonignorable missing
outcome problems (e.g. Scharfstein et al., 1999 [22]; Vansteelandt et al., 2007 [33]; Kim
and Yu, 2011 [7]; Scharfstein et al., 2014 [21]) and will here be used to address the fact
that L1 is missing in the control group. The expectation in the denominator is needed to
make sure that the density function P (S|L1, R = 0,C) integrates to 1.
Assumption (5) does not place a restriction on the observed data beyond the restriction
P (S|R = 0,C) = ∫ P (S|L1, R = 0,C)f(L1|R = 1,C)dL1 and that if P (S = 1|L1, R =
1,C) = 0 for certain L1 and C, P (S = 1|L1, R = 0,C) is also 0. In particular, from
P (S = 0|R = 0,C)
=
∫
P (S = 0|L1, R = 0,C)f(L1|R = 0,C)dL1
=
∫
P (S = 0|L1, R = 1,C) 1
E [exp {S(q0(C) + q1(L1,C))} |L1, R = 1,C]f(L
1|R = 1,C)dL1
= P (S = 0|R = 1,C)E
[
1
E [exp {S(q0(C) + q1(L1,C))} |L1, R = 1,C] |S = 0, R = 1,C
]
,
where we use that L1 ⊥ R|C, it follows that
E
[
(1−R)(1− S)
P (R = 0|C) −
R(1− S)
P (R = 1|C)
1
E [exp {S(q0(C) + q1(L1,C))} |L1, R = 1,C]
]
(6)
= E [P (S = 0|R = 0,C)
−E
(
1
E [exp {S(q0(C) + q1(L1,C))} |L1, R = 1,C] |S = 0, R = 1,C
)
P (S = 0|R = 1,C)
]
= 0.
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Therefore, the unknown parameter value λ0, indexing model q0(C;λ), can be consis-
tently estimated by solving estimating equation (6). Since the densities P (R|C) and
P (S|L1, R = 1,C) can be obtained from the observed data, it can be inferred from this
that λ is identifiable from the observed data when q1(L
1,C) is given. Since restriction
(6) is the only testable restriction on the observed data it further follows that q1(L
1,C)
is not identifiable from the observed data when q0(C) is left unspecified, and thus that
each choice of q1(L
1,C) is compatible with the observed data. After specifying q1(L
1,C)
and fitting a model pi(C; θˆ) for the probability P (R = 1|C) and a model l(L,C; ωˆ) for
P (S = 1|L, R = 1,C), the unknown parameter value λ0 indexing model q0(C;λ) can be
estimated by solving
0 =
n∑
i=1
ψ(Ci)
(
(1−Ri)(1− Si)
1− pi(Ci; θˆ)
−Ri(1− Si)
pi(Ci; θˆ)
1
l(Li,Ci; ωˆ)
{
exp
(
q0(Ci; λˆ) + q1(Li,Ci)
)
− 1
}
+ 1
 . (7)
In this equation, ψ is an arbitrary function of C of the same dimension as λ. For instance,
when e.g. q0(C;λ) = λ1 + λ
′
2C, ψ(C) = (1,C)
′ can be used. Note that the data of the
switchers is not used in this equation. Similarly, it can be shown that λ can be estimated
by solving estimating equations
0 =
n∑
i=1
ψ(Ci)
(
(1−Ri)Si
1− pi(Ci; θˆ)
− RiSi
pi(Ci; θˆ)
exp
(
q0(Ci; λˆ) + q1(Li,Ci)
)
l(Li,Ci; ωˆ)
{
exp
(
q0(Ci; λˆ) + q1(Li,Ci)
)
− 1
}
+ 1
 , (8)
using of the observed data of the switchers instead of the non-switchers. Depending on
the context equation (7) or (8) can lead to more accurate estimates for λ.
The weights W (S,L,C) can next be estimated as
W (S,L,C; λˆ, ωˆ) =
exp(S(q0(C; λˆ) + q1(L,C)))
E[exp(S(q0(C; λˆ) + q1(L,C)))|L, R = 1,C]
=
exp(S(q0(C; λˆ) + q1(L,C)))
l(L,C; ωˆ)
{
exp
(
q0(C; λˆ) + q1(L,C)
)
− 1
}
+ 1
.
Even when randomisation is done independently of the baseline covariates C, im-
provement in the precision of the inverse probability weighted means can be made by
using propensity scores P (R = 1|C) estimated under more flexible models (Rotnitzky
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et al., 2010 [18]). Therefore, it is in principle preferable to fit a parametric model
pi(C;θ) for the probability of assignment to the active treatment arm P (R = 1|C); e.g.
pi(C;θ) = expit(θ1 + θ
′
2C) and replace pˆi by pi(C; θˆ) in step 2 of the IPW approach in
section 4. Parameter µ1 can then be estimated as µˆ1 =
∑n
i=1 Yi
RiWi
pi(Ci,θˆ)
/
∑n
i=1
RiWi
pi(Ci,θˆ)
and
µ0 as µˆ0 =
∑n
i=1 Yi
1−Ri
1−pi(Ci,θˆ)/
∑n
i=1
1−Ri
1−pi(Ci,θˆ) .
The restriction of assumption (5) which states that if P (S = 1|L1, R = 1,C) = 0 for
certain L1 and C, P (S = 1|L1, R = 0,C) is also 0, might be violated when there is a large
imbalance in switching events in both groups. This is e.g. the case when nobody would
change to rescue medication when assigned to the experimental treatment arm of the
study, i.e. if there are no switchers under treatment, but some patients would change to
rescue medication when assigned to control. In that setting, it might better to target the
balanced estimand where the switching status is fixed to the natural value it would have
been under experimental treatment: E
(
Y 1 − Y 0S1
)
. This effect can simply be estimated
using the proposed IPW method, upon interchanging the meaning of variable R = 0 and
R = 1 in the dataset.
The sum of q0(C) and q1(L
1,C) can be interpreted as the log odds ratio for switching
for the control group versus the treatment group:
exp{q0(C) + q1(L1,C)} = odds(S = 1|R = 0,L
1,C)
odds(S = 1|R = 1,L1,C) . (9)
Here, q1(L
1,C) represents the extent to which the association between switching and
severity of disease under treatments differs between the two treatment groups:
exp{q1(L1,C)} = odds(S = 1|R = 0,L
1,C)/odds(S = 1|R = 1,L1,C)
odds(S = 1|R = 0,L1 = 0,C)/odds(S = 1|R = 1,L1 = 0,C) . (10)
The value L1 = 0 is a reference value, e.g. not severely ill under treatment.
The function q1(L
1,C) needs to be specified by the user since L1 is not observed for the
control patients. In this section, we discuss an extreme value for q1(L
1,C) and afterwards,
we propose a sensitivity analysis. From (10), it follows that the choice q1(L
1,C) ≡ 0
implies
odds(S = 1|R = 0,L1,C)
odds(S = 1|R = 1,L1,C) =
odds(S = 1|R = 0,L1 = 0,C)
odds(S = 1|R = 1,L1 = 0,C) ,
meaning that differences between the switching statuses in both treatment groups can be
fully assigned to the baseline covariates. This is generally implausible. In particular, if
patients are more seriously ill under control than under treatment, we expect odds ratios
in the numerator and denominator of (10) to be larger than one. The odds ratio in the
denominator is the odds ratio for patients who would not have been seriously ill under
treatment, e.g. L1 = 0. Since switching S is more weakly associated with L1 in the
control group than in the treatment group, we expect q1(L
1,C) to be smaller than 0.
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A.3 Influence function
In this section, we derive the influence function of the proposed IPW estimator of the
parameter µ. First, we derive the influence function of µˆ1.
Since
µˆ1 =
{
n∑
j=1
RjW (Sj,Lj,Cj; λˆ, ωˆ)/pi(Cj; θˆ)
}−1 n∑
i=1
YiRiW (Si,Li,Ci; λˆ, ωˆ)/pi(Ci; θˆ),
it holds that
0 =
1√
n
n∑
i=1
RiW (Si,Li,Ci; λˆ, ωˆ)/pi(Ci; θˆ)(Yi − µˆ1).
From the Taylor expansion around µ1, λ, ω and θ and the uniform WLLN (see Newey
and McFadden (1994 [10]), Lemma 4.3), we obtain
0 =
1√
n
n∑
i=1
YiRiWi(λ,ω)/pii(θ)−
√
nµ1
1
n
n∑
i=1
RiWi(λ,ω)/pii(θ)
+
1
n
n∑
i=1
Ri
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)
(Yi − µ1)
√
n
λˆ − λωˆ −ω
θˆ − θ

− 1
n
n∑
i=1
RiWi(λ,ω)/pii(θ)
√
n(µˆ1 − µ1) + op(1)
=
1√
n
n∑
i=1
YiRiWi(λ,ω)/pii(θ)−
√
nµ1
+
1
n
n∑
i=1
Ri
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)
(Yi − µ1)
√
n
λˆ − λωˆ −ω
θˆ − θ

−√n(µˆ1 − µ1) + op(1), (11)
where Wi(λ,ω) ≡ W (Si,Li,Ci;λ,ω) and pii(θ) ≡ pi(Ci;θ). Since parameter ω indexing
l(L,C;ω) = expit(ω1 +ω
′
2C +ω
′
3L) = P (S = 1|L, R = 1,C)
is unknown and substituted by the MLE, we have
√
n(ωˆ −ω) = 1√
n
n∑
i=1
E(Si,ωS
′
i,ω)
−1Si,ω + op(1). (12)
Here, Si,ω denotes the score vector for ω in individual i.
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Parameter λ = (λ1,λ2)
′ indexing P (S = 1|L1, R = 0,C) = expit(λ1 + λ′2C + ρω ′3L1) is
estimated by solving estimating equations. In particular, the estimator λˆ for the param-
eter λ is the solution to the estimating equations E(Uλ(S,L, R,C; λˆ, θˆ)) = 0 with
Uλ(S,L, R,C;λ,θ) =
(
1
C
)(
(1−R)S
1− pi(C;θ) −
RS
pi(C;θ)
exp (q0(C;λ) + q1(L,C))
l(L,C;ω) {exp (q0(C;λ) + q1(L,C))− 1}+ 1
)
.
Here, q0(C) = λ1− ω1 + (λ2−ω2)′C and q1(L,C) = (ρ− 1)ω ′3L. Parameter θ = (θ1, θ2)′,
indexing P (R = 1|C) = expit(θ1 + θ ′2C), is unknown and substituted by the MLE θˆ.
Therefore, this estimator is the solution to the estimating equations E(Uθ(R,C; θˆ)) = 0
with
Uθ(R,C;θ) =
(
1
C
)
(R− expit(θ1 + θ ′2C)).
In addition, we have
√
n(θˆ − θ) = 1√
n
n∑
i=1
E(Si,θS
′
i,θ)
−1Si,θ + op(1). (13)
Here, Si,θ = Uθ(Ri,Ci;θ) denotes the score vector for θ in individual i. Consequently,
the influence function for λ is given by
φλ(S,L, R,C)
= Uλ − E
(
∂Uλ
∂θ
)
E−1
(
∂Uθ
∂θ
)
Uθ
=
(
1
C
)(
(1−R)S
1− expit(θ1 + θ ′2C)
− RS
expit(θ1 + θ
′
2C)
exp (q0(C;λ) + q1(L,C))
l(L,C;ω) {exp (q0(C;λ) + q1(L,C))− 1}+ 1
)
+E
((
1 C′
C CC′
)[
(1−R)S(exp(θ1 + θ ′2C) + 1)
−RS(exp(−(θ1 + θ ′2C)) + 1)
exp (q0(C;λ) + q1(L,C))
l(L,C;ω) {exp (q0(C;λ) + q1(L,C))− 1}+ 1
])
×E−1
((
1 C′
C CC′
)
exp(θ1 + θ
′
2C)
(1 + exp(θ1 + θ
′
2C))
2
)(
1
C
)
(R− expit(θ1 + θ ′2C)).
As a consequence, we obtain
√
n(λˆ − λ) = 1√
n
n∑
i=1
φλ(Si,Li, Ri,Ci) + op(1). (14)
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Using (11), (12), (13), (14) and the uniform WLLN it follows that
√
n(µˆ1 − µ1)
=
1√
n
n∑
i=1
YiRiWi(λ,ω)/pii(θ)−
√
nE[Y
1S0i
i ]
+
1√
n
E
[
YiRi
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)] n∑
k=1
φλ(Sk,Lk, Rk,Ck)E(Sk,ωS′k,ω)−1Sk,ω
E(Sk,θS
′
k,θ)
−1Sk,θ

− 1√
n
E
[
Ri
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)] n∑
k=1
φλ(Sk,Lk, Rk,Ck)E(Sk,ωS′k,ω)−1Sk,ω
E(Sk,θS
′
k,θ)
−1Sk,θ

×E[YiRiWi(λ,ω)/pii(θ)] + op(1).
We conclude that µˆ1 is an asymptotically linear estimator of µ1 with influence function
φµ1(Yi, Si,Li, Ri,Ci;λ,ω)
= −E[Y 1S0ii ] + YiRiWi(λ,ω)/pii(θ)
+E
[
YiRi
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)]φλ(Si,Li, Ri,Ci)E(Si,ωS′i,ω)−1Si,ω
E(Si,θS
′
i,θ)
−1Si,θ

−E
[
Ri
(
∂Wi(λ,ω)/pii(θ)
∂λ
∂Wi(λ,ω)/pii(θ)
∂ω
∂Wi(λ,ω)/pii(θ)
∂θ
)]φλ(Si,Li, Ri,Ci)E(Si,ωS′i,ω)−1Si,ω
E(Si,θS
′
i,θ)
−1Si,θ

×E[YiRiWi(λ,ω)/pii(θ)]. (15)
Therefore, the asymptotic variance of µˆ1 can be calculated as one over n times the sample
variance of φµ1(Y, S,L, R,C; λˆ, ωˆ).
Since
Wj(λ,ω) =
(
expit(λ1 + λ
′
2Cj + ρω
′
3Lj)
expit(ω1 +ω ′2Cj +ω
′
3Lj)
)Sj (1− expit(λ1 + λ′2Cj + ρω ′3Lj)
1− expit(ω1 +ω ′2Cj +ω ′3Lj)
)1−Sj
pij(θ) = expit(θ1 + θ
′
2Cj),
it holds that
∂Wj(λ,ω)/pij(θ)
∂λ
=
1
pij(θ)
expit(λ1 + λ
′
2Cj + ρω
′
3Lj)
1 + exp(λ1 + λ
′
2Cj + ρω
′
3Lj)
(
1
expit(ω1 +ω ′2Cj +ω
′
3Lj)
)Sj
×
(
− 1
1− expit(ω1 +ω ′2Cj +ω ′3Lj)
)1−Sj (
1 C′j
)
,
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∂Wj(λ,ω)/pij(θ)
∂ω
=
(
∂Wj(λ,ω)/pij(θ)
∂ω1
∂Wj(λ,ω)/pij(θ)
∂ω1
C′j
∂Wj(λ,ω)/pij(θ)
∂ω3
)
,
with
∂Wj(λ,ω)/pij(θ)
∂ω1
=
1
pij(θ)
(
−expit(λ1 + λ
′
2Cj + ρω
′
3Lj)
exp(ω1 +ω ′2Cj +ω
′
3Lj)
)Sj
× ((1− expit(λ1 + λ′2Cj + ρω ′3Lj) exp(ω1 +ω ′2Cj +ω ′3Lj))1−Sj
∂Wj(λ,ω)/pij(θ)
∂ω3
= Lj
1
pij(θ)
 ρexpit(λ1+λ′2Cj+ρω ′3Lj)1+exp(λ1+λ′2Cj+ρω ′3Lj) − expit(λ1+λ′2Cj+ρω ′3Lj)1+exp(ω1+ω ′2Cj+ω ′3Lj)
expit(ω1 +ω ′2Cj +ω
′
3Lj)
Sj
×
 −ρexpit(λ1+λ′2Cj+ρω ′3Lj)1+exp(λ1+λ′2Cj+ρω ′3Lj) + (1− expit(λ1 + λ′2Cj + ρω ′3Lj))expit(ω1 +ω ′2Cj +ω ′3Lj)
1− expit(ω1 +ω ′2Cj +ω ′3Lj)
1−Sj ,
and
∂Wj(λ,ω)/pij(θ)
∂θ
= −Wj(λ,ω) exp(−(θ1 + θ ′2Cj))
(
1 C′j
)
.
Next, we derive the influence function of µˆ0. Since
µˆ0 =
{
n∑
j=1
(1−Rj)/(1− pi(Cj; θˆ))
}−1 n∑
i=1
Yi(1−Ri)/(1− pi(Ci; θˆ)),
it holds that
0 =
1√
n
n∑
i=1
1−Ri
1− pi(Ci; θˆ)
(Yi − µˆ0).
28
From the Taylor expansion around µ0 and θ and the uniform WLLN, we obtain
0 =
1√
n
n∑
i=1
1−Ri
1− pii(θ)(Yi − µ0) +
1√
n
n∑
i=1
(1−Ri) ∂
∂θ
(
1
1− pii(θ)
)
(Yi − µ0)
(
θˆ − θ
)
− 1√
n
n∑
i=1
1−Ri
1− pii(θ)(µˆ0 − µ0) + op(1)
=
1√
n
n∑
i=1
1−Ri
1− pii(θ)Yi −
√
nµ0
+
1
n
n∑
i=1
(1−Ri) ∂
∂θ
(
1
1− pii(θ)
)
(Yi − µ0)
√
n
(
θˆ − θ
)
−√n(µˆ0 − µ0) + op(1).
Consequently, from (13) and the uniform WLLN it follows that
√
n(µˆ0 − µ0)
=
1√
n
n∑
i=1
Yi(1−Ri)/(1− pii(θ))
+E
[
Yj(1−Rj) exp(θ1 + θ ′2Cj)
(
1 Cj
)] 1√
n
n∑
k=1
E(Sk,θS
′
k,θ)
−1Sk,θ
−E [(1−Rj) exp(θ1 + θ ′2Cj) (1 Cj)]E[Yj(1−Rj)/(1− pij(θ))] 1√n
n∑
k=1
E(Sk,θS
′
k,θ)
−1Sk,θ
+op(1)−
√
nE(Y 0j ).
As a consequence, µˆ0 is an asymptotically linear estimator of µ0 with influence function
φµ0(Yi, Ri,Ci;θ)
= −E(Y 0i ) + Yi(1−Ri)/(1− pii(θ))
+E
[
Yi(1−Ri) exp(θ1 + θ ′2Ci)
(
1 Ci
)]
E(Si,θS
′
i,θ)
−1Si,θ
−E [(1−Ri) exp(θ1 + θ ′2Ci) (1 Ci)]E[Yi(1−Ri)/(1− pii(θ))]E(Si,θS′i,θ)−1Si,θ .(16)
From (11) and (16), it follows that µˆ is an asymptotically linear estimator of µ with
influence function φµ(Y, S,L, R,C;λ,ω,θ) = φµ1(Y, S,L, R,C;λ,ω)−φµ0(Y,R,C;θ). The
asymptotic variance of µˆ can thus be calculated as one over n times the sample variance
of φµ(Y, S,L, R,C; λˆ, ωˆ, θˆ).
A.4 Sensitivity analysis
In this section, we show a data generating mechanism under which the choice of q1(L
1,C) =
(ρ− 1)ω ′3L1, proposed in the main paper, is justified. However, the settings under which
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this choice of q1(L
1,C) is correct are not limited to the settings discussed here.
We consider univariate variables L0 and L1 that are normally distributed conditional on
the baseline covariates. In addition, we define the correlation ρ := corr(L0, L1|C) between
the health statuses under both treatments. This correlation cannot be observed and will
be used as a sensitivity parameter. However, we expect a rather high correlation between
both health statuses. It follows that L0|L1,C is also normally distributed with mean
E(L0|L1,C) = E(L0|C) + ρ(L1 − E(L1|C))SD(L
0|C)
SD(L1|C)
and variance
var(L0|L1,C) = var(L0|C)(1− ρ2).
Suppose model q0(C) is linear in C, i.e. q0(C;ζ ) = ζ1 + ζ
′
2C, and q1(L
1,C) is linear in
L1, i.e. q1(L
1) = αL1 for some parameter value α. Using (5), this leads to the following
equality:
P (S = 1|L1, R = 0,C) = P (S = 1|L
1, R = 1,C) exp
(
ζ1 + ζ
′
2C + αL
1
)
P (S = 1|L1, R = 1,C){exp (ζ1 + ζ ′2C + αL1)− 1}+ 1 .
If the probability P (S = 1|L,R,C) follows a logistic regression model, i.e.
P (S = 1|L,R,C) = expit(ω1 +ω ′2C + ω3L+ ω4R), (17)
these choices for q0(C) and q1(L
1,C) imply that the probability to switch in the control
group conditional on L1 also follows a logistic regression model:
P (S = 1|L1, R = 0,C)
= expit(ω1 +ω
′
2C + ω3L+ ω4)
exp(ζ1 + ζ
′
2C + αL
1)
expit(ω1 +ω ′2C + ω3L+ ω4)
{
exp
(
ζ1 + ζ
′
2C + αL
1
)− 1}+ 1
= expit(ω1 + ω4 + ζ1 + (ω2 + ζ 2)
′C + (α + ω3)L1).
The assumed model in section 3 of the main paper corresponds to the choices λ1 =
ω1 + ω4 + ζ1 and λ2 = ω2 + ζ 2. If switching is rare, this probability can be approximated
by an exponential function:
P (S = 1|L1, R = 0,C) ≈ exp(ω1 + ω4 + ζ1 + (ω2 + ζ 2)′C + (α + ω3)L1). (18)
From (17), it also follows that
P (S = 1|L1, R = 0,C) =
∫
P (S = 1|L1, L0, R = 0,C)f(L0|L1, R = 0,C)dL0
= E
[
P (S = 1|L0, R = 0,C)|L1, R = 0,C]
= E
[
expit(ω1 +ω
′
2C + ω3L
0)|L1, R = 0,C] ,
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where the second equality follows from the assumption that if L0 is given, the decision
to switch is independent of L1 for a patient in the control group: S ⊥ L1|L0, R = 0,C.
This is a reasonable assumption since the decision to take rescue medication is based on
L0 and C for a patient in the control group. If switching is rare, this probability can be
approximated:
P (S = 1|L1, R = 0,C) ≈ E [exp(ω1 +ω ′2C + ω3L0)|L1, R = 0,C] .
Using the moment-generating function of a normally distributed variable, this leads to
the following approximation for the probability to switch in the control group:
P (S = 1|L1, R = 0,C)
≈ exp(ω1 +ω ′2C)E
[
exp(ω3L
0)|L1, R = 0,C]
= exp
(
ω1 + ρω3L
1 +ω ′2C + ω3(E(L
0|C)− ρE(L1|C) + 1
2
var(L0|C)(1− ρ2)ω3)
)
,
(19)
assuming var(L0|C) = var(L1|C). Comparing (18) to (19) , we obtain
q1(L
1,C) = αL1 = (ρ− 1)ω3L1,
and together with (17) we conclude that the effect of L1 on switching in the control group
is ρ times weaker than the effect of L0 on switching in the control group, conditional
on the baseline covariates. The same reasoning holds if model (17) uses an exponential
link function instead of an expit link function. However, the settings under which this
choice of q1(L
1,C) is correct are not limited to the settings discussed here. In particular,
this choice can also be correct in other settings, where L0 and L1 may not be normally
distributed, or switching is not rare. This motivates us to propose the following sensitivity
analysis for q1(L
1,C):
1. Fit a model for the probability of switching in the treatment group:
l(L1,C;ω) = P (S = 1|L1, R = 1,C),
e.g. l(L1,C;ω) = expit(ω1+ω
′
2C+ω
′
3L
1). Parameter ω ′3 is defined as the coefficient
of L1 in this model.
2. Let model q1(L
1,C) = (ρ − 1)ω ′3L1 vary for a range of values ρ. One could for
example test a range of values ρ ∈ [0.8, 1] since we expect a high correlation between
L1 and L0 conditional on the baseline covariates.
3. Repeat estimation of µ1 for each choice of q1(L
1,C).
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B Implementation in R
In this section, we show how data can be simulated and how the IPW estimator, proposed
in section 4, can be implemented. This is done in the software package R, Version 4.0.0.
Data simulation
We choose treatment R to be randomly assigned, with equal probability. Next, a baseline
covariate C is generated, following a standard normal distribution. Afterwards, the coun-
terfactual severity of disease under treatment is drawn for all patients, using a normal
distribution:
L1|C ∼ N(δ1 + δ2C, σ2L).
Next, S1 and Y 1 are generated for all patients. However, we will only use these values for
the patients in the treatment group.
S1|L1, R = 1, C ∼ Bin(expit(ω1 + ω2C + ω3L1))
Y 1|S1, L1, R = 1, C ∼ N(α1 + α2S1 + α3L1 + α4C, σ2Y ).
The decision to switch a patient in the control group, conditional on L1 can be generated
as follows:
S0|L1, R = 0, C ∼ Bin(expit(λ1 + λ2C + ρω3L1)),
with ρ the correlation between L1 and L0 conditional on the baseline covariates (see
appendix A.4). Next, the outcome for the patients in the control group can be drawn:
Y 0|S0, L1, R = 0, C ∼ N(α1 + α2S0 + α3L1 + α4C + α5, σ2Y ).
Finally, a dataset with the observed data for the patients in the control and treatment
group is constructed. The parameters of scenario 1, as shown in table 4 in appendix C.1,
are used.
delta1<- -0.5
delta2<- 0.1
sd.l<- 0.3
omega1<- -7
omega2<- -0.01
omega3<- -7
alpha1<- 0
alpha2<- 0.5
alpha3<- 2
alpha4<- 0.1
alpha5<- -0.5
lambda1<- -5
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lambda2<- -0.02
sd.y<- 0.3
rho<- 0.9
We set a seed to make the code reproducible and choose total sample size n = 1000.
install.packages("clusterPower")
library("clusterPower")
set.seed(123)
n<-1000
R<-rbinom(n,1,0.5)
C<-rnorm(n,0,1)
L.one<-rnorm(n,delta1+delta2*C,sd.l)
#treatment group
S.one<-rbinom(n,1,expit(omega1+omega2*C+omega3*L.one))
Y.one<-rnorm(n,alpha1+alpha2*S.one+alpha3*L.one+alpha4*C,sd.y)
#control group
S.zero<-rbinom(n,1,expit(lambda1+lambda2*C+rho*omega3*L.one))
Y.zero<-rnorm(n,alpha1+alpha2*S.zero+alpha3*L.one+alpha4*C+alpha5,sd.y)
#observed data
L<-ifelse(R==1,yes=L.one,no=NA)
S<-R*S.one+(1-R)*S.zero
Y<-R*Y.one+(1-R)*Y.zero
data<-data.frame(R,C,L,S,Y)
The following display shows the data structure:
head(data)
R C L S Y
1 0 -0.60189285 NA 0 -1.9228484239
2 1 -0.99369859 -0.6915470 1 -1.0807910570
3 0 1.02678506 NA 1 -0.8404511436
4 1 0.75106130 -0.2367732 0 -0.6076257387
5 1 -1.50916654 -0.3148101 0 -0.0009898745
6 0 -0.09514745 NA 0 0.1251228824
For the patients in the control group (R = 0), L is missing. This is not a problem, since
the observed L in the control group is not used to estimate µ. However, to make the rest
of the implementation easier, we will replace these values by 0.
L<-ifelse(R==1,yes=L,no=0)
data$L<-L
head(data)
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R C L S Y
1 0 -0.60189285 0.0000000 0 -1.9228484239
2 1 -0.99369859 -0.6915470 1 -1.0807910570
3 0 1.02678506 0.0000000 1 -0.8404511436
4 1 0.75106130 -0.2367732 0 -0.6076257387
5 1 -1.50916654 -0.3148101 0 -0.0009898745
6 0 -0.09514745 0.0000000 0 0.1251228824
The treatment policy estimand or intention-to-treat effect can easily be calculated:
mean(subset(data,R==1)$Y)-mean(subset(data,R==0)$Y)
0.4001212
In the next section, we illustrate how the novel estimand can be estimated using the IPW
estimator proposed in section 4.
IPW estimator
Step 1: fit model l(L,C,ω) for the probability of switching in the treatment group P (S =
1|L,R = 1, C) and save the predictions.
fit.l<-glm(S~L+C,data=subset(data,R==1),family = binomial(link="logit"))
prob.l<-predict(fit.l,newdata=data.frame(C=data$C,L=data$L),type="response")
omega1.estimate<-coef(fit.l)["(Intercept)"]
omega2.estimate<-coef(fit.l)["C"]
omega3.estimate<-coef(fit.l)["L"]
The coefficients in this model are saved to use in the next step.
Step 2: Calculate sample mean of R: pˆi = n−1
∑n
i=1Ri for all patients across both treat-
ment groups.
prob.pi<-dim(subset(data,R==1))[1]/dim(data)[1]
Estimate parameter λ = (λ1, λ2)
′ by solving estimating equations. Therefore, we define a
function that takes a value for λ1 and λ2 as input and returns the obtained values for
0 =
n∑
i=1
(
1
Ci
)(
(1−Ri)(1− Si)
1− pˆi
− 1
pˆi
Ri(1− Si)
expit(ωˆ1 + ωˆ2Ci + ωˆ3Li) {exp (λ1 − ωˆ1 + (λ2 − ωˆ2)Ci + (ρ− 1)ωˆ3Li)− 1}+ 1
)
,
corresponding to these λ1 and λ2.
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IPW.lambda<-function(x){
lambda1<-as.numeric(x[1])
lambda2<-as.numeric(x[2])
q0<-lambda1-omega1.estimate+(lambda2-omega2.estimate)*C
q1<-(rho-1)*omega3.estimate*L
main<-(1-R)*(1-S)/(1-prob.pi)-(R/prob.pi)*(1-S)/(prob.l*(exp(q0+q1)-1)+1)
return(c(sum(main),sum(C*main)))
}
Now λ1 and λ2 can be estimated by solving the estimating equations using the nleqslv
function. We choose λ1 = 0 and λ2 = 0 as start values for the algorithm.
install.packages("nleqslv")
library("nleqslv")
lambda<-nleqslv(fn=IPW.lambda, x=c(0,0))$x
Step 3: estimate the weights W (S, L, C).
q0<-lambda[1]-omega1.estimate+(lambda[2]-omega2.estimate)*C
q1<-(rho-1)*omega3.estimate*L
W<-S*exp(q0+q1)/(prob.l*(exp(q0+q1)-1)+1)+(1-S)/(prob.l*(exp(q0+q1)-1)+1)
Step 4: estimate µ1.
mu1<-mean(Y*R*W)/mean(R*W)
mu1
-0.8871583
Step 6: estimate µ0.
mu0<-mean((1-R)*Y)/mean(1-R)
mu0
-1.354372
Finally, µ can be estimated.
mu<-mu1-mu0
mu
0.4672135
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C Simulations
C.1 Scenarios
Parameter Scenario 1 Scenario 2 Scenario 3
δ1 -0.5 -0.5 -0.5
δ2 0.1 0.1 0.2
σL 0.3 0.3 0.3
ω1 -7 -9 -7
ω2 -0.01 -0.01 -0.01
ω3 -7 -12 -11
α1 0 0 0
α2 0.5 0.5 0.7
α3 2 2 2
α4 0.1 0.1 0.1
α5 -0.5 -0.4 -0.7
σY 0.3 0.3 0.3
λ1 -5 -5 -2
λ2 -0.02 -0.02 -0.02
Balanced estimand (ρ = 0.9)
µ1 -0.879 -0.728 -0.462
µ0 -1.379 -1.129 -1.161
µ 0.500 0.401 0.699
Treatment policy estimand
E(Y 1) -0.946 -0.881 -0.744
E(Y 0) -1.379 -1.129 -1.161
E(Y 1 − Y 0) 0.433 0.248 0.417
Table 4: The parameter values for the different scenarios, together with the
corresponding balanced and treatment policy estimand.
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Figure 2: Illustration of the three scenarios. At the left pictures, the mean change from
baseline in the cognitive score is shown. The change in score at month 26 is the health
status L, while the change in score at month 54 is the outcome Y . At the right pictures,
the probability to switch in function of L1 is displayed.
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Figure 3: Illustration of the three scenarios. The histograms of L1 are shown.
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C.2 Results
Figure 4: Boxplots showing the results of the simulations investigating the finite sample
size performance of the IPW estimator for µ0, µ1 and µ = µ1 − µ0. The red horizontal
lines indicate the true parameter values.
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Scenario Sample Parameter Bias SE Weights
size
Scenario 1 200 µ -0.008 0.098
Large treatment effect
Limited switching effect
Switchers:
11% in R = 1
24% in R = 0
µ1 -0.007 0.076 0.437; 1.642
µ0 0.001 0.064
1000 µ -0.006 0.043
µ1 -0.006 0.033 0.508; 1.895
µ0 0 0.028
Scenario 2 200 µ -0.042 0.099
Small treatment effect
Limited switching effect
Switchers:
24% in R = 1
54% in R = 0
µ1 -0.042 0.081 0.054; 2.132
µ0 0.001 0.059
1000 µ -0.035 0.044
µ1 -0.034 0.035 0.088; 2.240
µ0 0 0.026
Scenario 3 200 µ -0.123 0.114
Large treatment effect
Large switching effect
Switchers:
36% in R = 1
76% in R = 0
µ1 -0.122 0.103 0.010; 2.398
µ0 0.001 0.065
1000 µ -0.105 0.052
µ1 -0.105 0.046 0.023; 2.424
µ0 0 0.029
Table 6: Results of the simulations investigating the finite sample size performance of
the IPW estimator proposed in section 4, with truncated weights Wi at the 1% and 99%
percentiles. The column ‘weights’ shows the 5% and 95% percentiles of the weights
Wi/n
−1∑n
j=1RjWj among the patients in the experimental treatment arm.
D Data Analysis
D.1 Estimands framework
The balanced, treatment policy and hypothetical estimand used in the data analysis
(section 6 of the main paper) can be defined according to the guidelines of the ICH
E9(R1) addendum. These estimands only differ in the way in which the intercurrent
event ‘switching to rescue medication’ is handled:
• Treatment: canagliflozin 100 mg or placebo, as defined by the study protocol.
• Population: the entire study population, as defined by the inclusion-exclusion
criteria of the study.
41
• Variable: change from baseline in HbA1c (%) at week 26.
• Intercurrent events:
– Study discontinuation
The hypothetical scenario is envisaged where patients would not discontinue.
– Switching to rescue medication
∗ Balanced estimand:
The hypothetical scenario is envisaged where patients on the placebo arm
had been switched to rescue medication if and only if they would have
been switched when randomised to canagliflozin 100 mg.
∗ Treatment policy estimand:
All observed values of the variable are of interest, regardless of whether or
not the patient had initiated rescue medication.
∗ Hypothetical estimand:
The hypothetical scenario is envisaged where patients would not switch to
rescue medication.
• Population-level summary: difference in means of the variable.
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D.2 Materials and methods
Placebo CANA 100 mg CANA 300 mg Total
Characteristic (n = 192) (n = 195) (n = 197) (n = 584)
Sex, n (%)
Male 88 (45.8) 81 (41.5) 89 (45.2) 258 (44.2)
Female 104 (54.2) 114 (58.5) 108 (54.8) 326 (55.8)
Race, n (%)
White 134 (69.8) 124 (63.6) 137 (69.5) 395 (67.6)
Black or African 9 (4.7) 18 (9.2) 14 (7.1) 41 (7.0)
Asian 29 (15.1) 27 (13.8) 29 (14.7) 85 (14.6)
Other 20 (10.4) 26 (13.3) 17 (8.6) 63 (10.8)
Age (years), Mean (sd) 55.7 (10.9) 55.1 (10.8) 55.3 (10.2) 55.4 (10.6)
HbA1c (%), Mean (sd) 8.0 (1.0) 8.1 (1.0) 8.0 (1.0) 8.0 (1.0)
FPG (mmol/l), Mean (sd) 9.3 (2.1) 9.6 (2.4) 9.6 (2.4) 9.5 (2.3)
Body weight (kg), Mean (sd) 87.6 (19.5) 85.8 (21.4) 86.9 (20.5) 86.8 (20.4)
BMI (kg/m2), Mean (sd) 31.8 (6.2) 31.3 (6.6) 31.7 (6.0) 31.6 (6.2)
Duration of diabetes 25 (13.0) 23 (11.8) 20 (10.2) 68 (11.6)
≥ 10 years, n (%)
On AHA at screening, n (%) 92 (47.9) 94 (48.2) 95 (48.2) 281 (48.1)
Participating 76 (39.6) 79 (40.5) 80(40.6) 235 (40.2)
in FS-MMTT, n (%)
GFR (ml/min/1.73m2), 86.0 (21.5) 88.5 (20.2) 86.6 (19.1) 87.1 (20.3)
Mean (sd)
Smoker, n (%) 22 (11.5) 34 (17.4) 21 (10.7) 77 (13.2)
Systolic BP ≥ 140 mmHg, 46 (24.0) 52 (26.7) 51 (25.9) 149 (25.5)
n (%)
SHDL (mmol/l), Mean (sd) 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3)
STRIG (mmol/l), Mean (sd) 2.3 (1.3) 2.0 (1.3) 2.0 (1.1) 2.1 (1.2)
PPG (mmol/l), Mean (sd) 13.8 (3.9) 14.2 (4.4) 14.2 (4.1) 14.1 (4.2)
Table 7: Baseline and disease characteristics of patients in the canagliflozin study.
AHA, antihyperglycaemic agent; BMI, body mass index; BP, blood pressure; CANA,
canagliflozin; FPG, fasting plasma glucose; FS-MMTT, frequently-sampled mixed-meal
tolerance test; GFR, glomerular filtration rate; HbA1c, haemoglobin A1c; PPG, plasma
glucose - MMTT at 2 hour; SHDL, serum HDL cholesterol; STRIG, serum triglycerides.
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Placebo CANA 100 mg Total
Characteristic (n = 192) (n = 195) (n = 387)
FPG
Baseline 0 0 0
Week 6 9 (4.6) 8 (4.1) 17 (4.4)
Week 12 15 (7.8) 16 (8.2) 31 (8.0)
Week 18 23 (12.0) 20 (10.3) 43 (11.1)
Week 26 60 (31.3) 35 (18.0) 95 (24.5)
HbA1c
Baseline 0 0 0
Week 6 3 (1.6) 7 (3.6) 10 (2.6)
Week 12 12 (6.3) 13 (6.7) 25 (6.5)
Week 18 19 (9.9) 17 (8.7) 36 (9.3)
Week 26 29 (15.1) 25 (12.8) 54 (14.0)
PPG
Baseline 10 (5.2) 6 (3.1) 16 (4.1)
Week 26 72 (37.5) 39 (20) 111 (28.7)
SHDL
Baseline 0 0 0
Week 26 30 (15.6) 26 (13.3) 56 (14.5)
STRIG
Baseline 0 0 0
Week 26 30 (15.6) 25 (12.8) 55 (14.2)
Table 8: Number (%) of missing values in the longitudinal variables.
CANA, canagliflozin; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; PPG,
plasma glucose - MMTT at 2 hour; SHDL, serum HDL cholesterol; STRIG, serum
triglycerides.
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Figure 5: Mean change in HbA1c over time based on the first imputed dataset. Plots for
the other imputed datasets are very similar.
(a) Complete data (b) First imputed dataset
Figure 6: Change in HbA1c over time for (a) the patients without missing HbA1c values
(b) the first imputed dataset. The line turns green from the first study visit after
initiation of rescue medication. Plots for the other imputed datasets are very similar.
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(a) Complete data (b) First imputed dataset
Figure 7: Change in FPG over time for (a) the patients without missing FPG values (b)
the first imputed dataset. The line turns green from the first study visit after initiation
of rescue medication. Plots for the other imputed datasets are very similar.
D.3 Treatment policy estimand
In the treatment policy or intention-to-treat estimand regarding the intercurrent event
‘switching to rescue medication’, the initiation of rescue medication is considered irrelevant
in defining the treatment effect of interest: E(Y 1 − Y 0).
Assuming consistency and no unmeasured confounders between treatment and outcome
(Y r ⊥ R|C for r ∈ {0, 1}), as is guaranteed by randomised assignment, the treatment
policy estimand can be expressed as
E(Y 1 − Y 0) = E
(
Y
R
P (R = 1|C)
)
− E
(
Y
1−R
P (R = 0|C)
)
.
Therefore, we propose the following IPW estimator for the treatment policy estimand:
n∑
i=1
Yi
Ri
pˆi(Ci)
/
n∑
i=1
Ri
pˆi(Ci)
−
n∑
i=1
Yi
1−Ri
1− pˆi(Ci)/
n∑
i=1
1−Ri
1− pˆi(Ci) .
In the data-analysis, the same 50 imputed datasets were used as for the estimation of
the balanced estimand. For each of these datasets, the treatment policy effect was es-
timated and standard errors are obtained from 1000 nonparametric stratified bootstrap
replications. The results are combined using Rubin’s rules. The 95% confidence intervals
are estimated as percentile intervals from the pooled sample of 50×1000 estimates of the
treatment policy effect.
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D.4 Hypothetical estimand
The hypothetical estimand regarding the intercurrent event ‘switching to rescue medica-
tion’ corresponds to the hypothetical scenario where patients would not switch to rescue
medication: E(Y 10 − Y 00).
Identification of this hypothetical estimand relies on consistency and assumptions
Y r0 ⊥ R|Lr,C
Lr ⊥ R|C
Y r0 ⊥ S|L, R,C.
The first two assumptions are guaranteed by randomisation. The last assumption states
that the complier status of a patient can be fully attributed to the baseline covariates,
measured confounders and the treatment group in the sense that it has no residual depen-
dence on the potential outcomes Y r0. Using these assumptions, the hypothetical estimand
can be expressed as
E(Y 10 − Y 00)
=
∫
E(Y 10|L1,C)f(L1|C)f(C)dL1dC−
∫
E(Y 00|L0,C)f(L0|C)f(C)dL0dC
= E
(
Y
R
P (R = 1|C)
1− S
P (S = 0|L, R = 1,C)
)
− E
(
Y
1−R
P (R = 0|C)
1− S
P (S = 0|L, R = 0,C)
)
.
Therefore, we propose the following IPW estimator for the hypothetical estimand:
n∑
i=1
Yi
Ri
pˆi(Ci)
1− Si
Pˆ (Si = 0|Li, Ri = 1,Ci)
/
n∑
i=1
Ri
pˆi(Ci)
1− Si
Pˆ (Si = 0|Li, Ri = 1,Ci)
−
n∑
i=1
Yi
1−Ri
1− pˆi(Ci)
1− Si
Pˆ (Si = 0|Li, Ri = 0,Ci)
/
n∑
i=1
1−Ri
1− pˆi(Ci)
1− Si
Pˆ (Si = 0|Li, Ri = 0,Ci)
,
where Pˆ (Si = 0|Li, Ri = 1,Ci) and Pˆ (Si = 0|Li, Ri = 0,Ci) are obtained by regressing
the switching status on the variables L and C in the treatment or placebo group using
logistic regression. The probability to switch in the placebo group, i.e. P (S = 1|L, R =
0,C), is estimated using backward elimination, in the same way as for the balanced
estimand (see section 6 in the main paper). Since in the full model for the probability
to switch in the treatment group, i.e. P (S = 1|L, R = 1,C), all predictors had a p-value
of 99%, we decided to perform forward elimination, starting from the model with FPG
as only predictor. This logistic model was fitted in every imputed dataset and pooled
using Rubin’s rules. Next, in each step 1 variable was added to the model and kept
if the corresponding p-value in the pooled model was below 10%. Next, all two-by-two
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interactions between the variables in the model were each in turn added to the model
and kept if the corresponding p-value was below 10%. Afterwards, the hypothetical effect
was estimated for every imputed dataset and standard errors are obtained from 1000
nonparametric stratified bootstrap replications. Stratification was performed according
to whether subjects were taking AHAs at screening and whether they participated in
the frequently-sampled mixed-meal tolerance test (FS-MMTT). The results are combined
using Rubin’s rules. The 95% confidence intervals are estimated as percentile intervals
from the pooled sample of 50×1000 estimates of the hypothetical effect.
D.5 Results
Dependent variable: switching status S
Variable Coefficient (Standard error)
Intercept −9.228(2.551)∗∗∗
AGE −0.064(0.031)∗
AHASTRAT −1.467(0.631)∗
BLFPG −1.083(0.282)∗∗∗
SNSBPHFL 1.786(0.748)∗
BLSTRIG −0.433(0.243)∗
FPG 2.249(0.417)∗∗∗
Observations 192
Table 9: Logistic regression results for the pooled model for P (S = 1|L, R = 0,C).
Predictors: AGE, age in years; AHASTRAT, stratification factor: whether or not
patient was taking antihyperglycaemic agents at screening (reference: yes); BLFPG,
fasting plasma glucose value at baseline (mmol/l); BLSTRIG, serum triglycerides at
baseline (mmol/l); FPG, average fasting plasma glucose value (mmol/l) (for switchers:
average before switching, for non-switchers: average before week 26); SNSBPHFL,
systolic blood pressure ≥ 140 mmHg at screening (reference: no).
Significance codes: ∗p < 0.05, ∗∗p < 0.01 , ∗∗∗p < 0.001
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Coefficient
Variable ρ = 1 ρ = 0.9 ρ = 0.8
Intercept -35.826 -33.988 -32.305
AGE 0.335 0.322 0.312
AHASTRAT 3.061 3.056 3.074
BLFPG -1.908 -1.740 -1.578
SNSBPHFL -4.725 -4.457 -4.201
BLSTRIG 3.008 2.889 2.790
FPG 2.158 1.943 1.727
Table 10: Logistic regression results for P (S = 1|L0, R = 1,C) for the first imputed
dataset. Differences with the parameter values for the other imputed datasets are very
limited.
Figure 8: Histogram of the weights W (S,L,C) used to estimate the balanced estimand
(ρ = 0.9). Weights are shown for the patients in the placebo arm of the study using the
first imputed dataset. Differences with the plots for the other imputed datasets and
other values for the sensitivity parameter ρ are limited.
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Dependent variable: switching status S
Variable Coefficient (Standard error)
Intercept −8.478(3.955)∗
BLGFR −0.055(0.030)
FPG 0.974(0.363)∗∗
Observations 195
Table 11: Logistic regression results for the pooled model for P (S = 1|L, R = 1,C),
used to estimate the hypothetical estimand.
Predictors: BLGFR, glomerular filtration rate at baseline (ml/min/1.73m2); FPG,
average fasting plasma glucose value (mmol/l) (for switchers: average before switching,
for non-switchers: average before week 26).
Significance codes: ∗p < 0.05, ∗∗p < 0.01 , ∗∗∗p < 0.001
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